风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 11月19日，港股创新药ETF（513120）跌0.52%，成交额53.53亿元。当日份额增加2150.00万份，最新份 额为186.36亿份，近20个交易日份额增加19.75亿份。最新资产净值计算值为249.97亿元。 来源：新浪基金∞工作室 港股创新药ETF（513120）业绩比较基准为同期中证香港创新药指数收益率(人民币计价)，管理人为广 发基金管理有限公司，基金经理为刘杰，成立（2022-07-01）以来回报为34.12%，近一个月回报 为-2.04%。 ...

受外围影响，避险资产同样吸金。Wind数据显示，上海金ETF（518600）单日获资金净买入1.45亿元， 其已连续4个交易日获资金净买入，最新规模达38.2亿元，年内回报达49.71%。拉长周期看，上海金 ETF（518600）在过去3个完整自然年度（2022-2024）收益分别为8.41%、15.36%、26.63%，展示较好 避险属性。 展望后市，华泰证券策略团队认为，近期A股受到宏观不确定性影响进入缩量震荡阶段，短期市场变数 仍存，但从市场情绪指标来看，量化策略及全市场的赚钱效应指标已回落至中性区间。考虑到资金"抄 底"意愿仍存，投资者情绪回调幅度或相对有限，调整仍是配置机会。在此背景下，投资者仓位可适度 向"哑铃配置"迁移。一方面，在政策及交易因素叠加催化下，科技或仍为短期市场主线，恒生科技、A 股算力、机器人等方向的低位标的或是市场主要配置方向；另一方面，考虑到后续可能出现的外部不确 定性，具备防御性的红利板块或仍有配置机会。 免责声明：以上内容为本网站转自其他媒体，相关信息仅为传递更多信息之目的，不代表本网观点，亦 不代表本网站赞同其观点或证实其内容的真实性。如稿件版权单位或个人不想在本网发布， ...

Core Insights - Southbound capital has been a significant source of inflow into the Hong Kong stock market, with a cumulative net inflow exceeding 1.27 trillion HKD this year, marking a historical high for annual net inflows [1] - The innovative drug, technology, and non-bank sectors have seen substantial gains, with respective year-to-date increases of 79%, 53%, and 34%, compared to a 26% rise in the Hang Seng Index [1] - The largest Hong Kong innovative drug ETF (513120) received a net inflow of 585 million HKD in a single day, bringing its total size to 23.7 billion HKD [1] Fund Flows - The total net inflow for all ETFs in the market exceeded 3.777 billion HKD, with significant inflows into non-bank financials, innovative drugs, and technology sectors [1] - GF Fund Management led all public institutions with a total net inflow of 1.997 billion HKD across its ETFs, including those focused on A-shares and other sectors [2] - Notable ETFs under GF Fund Management include the innovative drug ETF (515120), low-fee创业板 ETF (159952), and the largest media ETF (512980), each receiving over 100 million HKD in net inflows [2] Market Outlook - Market volatility has increased entering November, with industry experts suggesting that fundamental improvements in 2026 may drive further gains in the Hong Kong stock market [2] - The AI industry is expected to catalyze improvements in net asset return rates (ROE) for sectors represented by the Hang Seng Technology Index, potentially leading to higher market valuations [2] - In terms of asset allocation, while the technology sector remains favorable, innovative drugs, non-bank financials, and certain cyclical assets are also worth attention [2]

Core Insights - The article discusses the current state of the innovative drug sector, highlighting the shift in market sentiment from optimism to caution, raising questions about whether this is a risk accumulation or an opportunity for investment [1] Group 1: Industry Overview - The innovative drug industry in China has evolved significantly over the past decade, transitioning from a position of lagging behind global standards to achieving leadership in certain areas [5] - The industry has undergone a complete cycle influenced by policy guidance, procurement pressures, and regulatory adjustments since the milestone event of "722 clinical data verification" in 2015, now being recognized as a "strategic emerging industry" [5] - The internationalization capability, exemplified by "License-out" strategies, has become a key factor in determining the value of companies within the sector [5] Group 2: Investment Strategies - Current adjustments in the innovative drug sector have made the "odds" of investment more attractive, although a repeat of the previous quarter's rapid growth may be challenging [6] - Investors are encouraged to utilize increasingly diverse ETF and index tools to mitigate risks and capture overall industry growth opportunities [5][9] - The Hong Kong stock market is highlighted as a favorable platform for investing in innovative drugs due to its unique advantages, including access to quality targets and international funding recognition [9] Group 3: Market Potential - The Chinese innovative drug market is projected to grow into a trillion-dollar sector, driven by increasing clinical demand, improved payment capabilities, and supportive policies [9] - Historical performance indicates that the Hong Kong innovative drug sector exhibits unique volatility characteristics, responding significantly during market rebounds and major academic conferences [10] Group 4: Advisory Services - The role of investment advisors is emphasized as crucial in transforming deep insights from analysts and fund managers into actual returns for clients, focusing on selecting the right sectors, timing, and investment tools [13] - A systematic approach combining sector selection, timing, and fund manager choice can significantly enhance annual excess returns for clients [13]

Core Insights - The cross-border ETF market has seen significant growth in 2023, with total assets surpassing 900 billion yuan by October 30, driven by increased demand for diversified asset allocation amid changing global economic dynamics [1] - GF Fund has established itself as a leading player in the cross-border ETF space, managing 10 cross-border ETFs with a total scale of 100.77 billion yuan, ranking it among the top in the industry [1][2] Product Overview - GF Fund's four major cross-border ETFs focus on popular sectors, including the largest Nasdaq ETF (159941) with a scale of 30.77 billion yuan, targeting major tech companies like Apple and Microsoft [2] - The Hong Kong Innovative Drug ETF (513120) has a scale of 22.8 billion yuan, benefiting from the upward trend in the global innovative drug industry [2] - The Hong Kong Non-Bank Financial ETF (513750) has a scale of 21.9 billion yuan, focusing on non-bank financial institutions in the Hong Kong market [2] - The Hang Seng Technology ETF (513380) also exceeds 10 billion yuan, capturing opportunities in leading tech companies in Hong Kong [2] Market Trends - The Hang Seng Hong Kong Stock Connect Technology Index has outperformed, with a 57% increase over the past year, reflecting strong investor interest in technology stocks [3] - Cross-border ETFs are increasingly favored by investors for their transparency, flexibility, and lower costs, serving as important tools for risk diversification and capturing overseas market opportunities [3]

来源：新浪基金∞工作室 港股创新药ETF（513120）业绩比较基准为同期中证香港创新药指数收益率(人民币计价)，管理人为广 发基金管理有限公司，基金经理为刘杰，成立（2022-07-01）以来回报为38.90%，近一个月回报 为-7.09%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 10月21日，港股创新药ETF（513120）涨1.30%，成交额61.46亿元。当日份额减少2700.00万份，最新份 额为165.22亿份，近20个交易日份额增加3.27亿份。最新资产净值计算值为229.51亿元。 ...

10月13日，港股创新药ETF（513120）跌3.40%，成交额52.41亿元。当日份额增加2.59亿份，最新份额 为164.71亿份，近20个交易日份额增加26.50亿份。最新资产净值计算值为234.21亿元。 来源：新浪基金∞工作室 港股创新药ETF（513120）业绩比较基准为同期中证香港创新药指数收益率(人民币计价)，管理人为广 发基金管理有限公司，基金经理为刘杰，成立（2022-07-01）以来回报为42.19%，近一个月回报 为-7.00%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 ...

来源：新浪基金∞工作室 9月26日，港股创新药ETF（513120）跌1.60%，成交额67.03亿元。当日份额减少2500.00万份，最新份 额为164.07亿份，近20个交易日份额增加26.55亿份。最新资产净值计算值为240.04亿元。 港股创新药ETF（513120）业绩比较基准为同期中证香港创新药指数收益率(人民币计价)，管理人为广 发基金管理有限公司，基金经理为刘杰，成立（2022-07-01）以来回报为46.29%，近一个月回报 为-2.76%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 ...

Group 1 - Recent market fluctuations have led to significant capital inflows into undervalued sectors such as non-bank financials, batteries, and innovative pharmaceuticals, with leading products attracting substantial investment [1] - On September 8, the Battery ETF (159755) saw a net inflow of over 1.4 billion yuan, ranking first in the market, with a total size reaching 9.3 billion yuan; similarly, the Hong Kong Innovative Pharmaceutical ETF (513120) had a net inflow exceeding 1.1 billion yuan, with a total size surpassing 22 billion yuan [1] - On September 9, the non-bank sector attracted significant capital, with the Hong Kong Stock Connect Non-Bank ETF (513750) receiving a net inflow of 921 million yuan, bringing its total size to a historical high of 21.4 billion yuan, with cumulative net inflows exceeding 19 billion yuan this year [1] Group 2 - Looking ahead, the market's fundamental signals are becoming clearer, with expectations of monetary and fiscal expansion in Europe and the U.S. in September, alongside China's "anti-involution" and clearer consumption pathways [2] - Three key investment directions are highlighted: first, physical assets benefiting from domestic operational improvements and overseas interest rate cuts, including non-ferrous metals (copper, aluminum, gold) and capital goods (lithium batteries, wind power equipment, engineering machinery, heavy trucks, photovoltaics) [2] - Second, opportunities are expected to emerge in domestic demand-related sectors such as food and beverages, tourism, and scenic spots following profit recovery [2] - Third, the long-term asset side of insurance is anticipated to benefit from a rebound in capital returns, with a focus on investment opportunities in the non-bank sector, particularly in insurance and brokerage firms [2]

Group 1 - The core viewpoint of the articles highlights the significant growth in profits for innovative drug and CXO companies in Hong Kong, driven by favorable factors such as BD transactions, breakthroughs in AI pharmaceutical technology, and optimized healthcare policies [1] - Approximately 110 Hong Kong-listed biopharmaceutical companies released interim performance reports, with nearly 70 companies reporting year-on-year revenue growth, and about 10 companies achieving revenue growth exceeding 100% [1] - The China Hong Kong Innovative Drug Index (CNY) has seen a cumulative increase of 106.5% year-to-date, outperforming the Hang Seng Composite Index by 77.83 percentage points as of September 4 [1] Group 2 - The largest Hong Kong innovative drug ETF (513120) has experienced a year-to-date increase of over 107%, ranking first among Wind's secondary investment types, with its latest scale surpassing 20.5 billion [1] - The ETF tracks the China Hong Kong Innovative Drug Index, benefiting from both low valuation advantages and strong fundamental earnings [1] - The index's price-to-earnings ratio stands at 35.93 times, positioned at the 37th percentile historically, indicating attractive valuation [1] Group 3 - Analysts from Wanlian Securities note that apart from a few large hybrid innovative drug leaders, some biotech companies like 3SBio, Innovent Biologics, and BeiGene have already achieved profitability [2] - These three innovative drug giants are among the top ten weighted stocks in the Hong Kong innovative drug ETF (513120), which collectively accounts for over 70% of the index's weight [2] - Institutions are optimistic about the sustainable growth of the innovative drug sector, with expectations for continued performance in the second half of the year [2] Group 4 - The Hong Kong innovative drug ETF (513120) offers an efficient way for investors to participate in the biotech sector, combining both technology and pharmaceutical attributes, making it suitable for medium to long-term capital allocation [3] - The ETF provides significant risk diversification compared to individual stock investments and can adapt flexibly to market style rotations [3] - As more innovative drug companies reach profitability between 2025 and 2027, the growth potential of the sector is expected to expand further [3]